To determine if a similar enhancement of therapy could be achieved with lower doses of IL-2, we treated tumor-bearing mice with Tri-mAb in combination with low dose (10,000 IU) or medium dose (50,000 IU) or high dose (100,000 IU) IL-2 daily for 5 days and monitored survival. The gene discussed is IL2; the disease is neoplasm.